
Ascendo Biotechnology is a clinical-stage biopharmaceutical company developing first-in-class immunotherapies that harness innate immunity to treat cancer and autoimmune diseases. Our proprietary platform centers on CD11b, a novel innate immune checkpoint, with two drug candidates in development. ASD141 is a first-in-class anti-CD11b monoclonal antibody for advanced solid tumors. By releasing the CD11b innate immune brake, ASD141 activates dendritic cells and mobilizes the stem-like T cell reservoir — rebuilding durable anti-tumor immunity, including in patients resistant to existing…
Annual Revenue$10M to $25M
Estimated OwnershipPrivateBuilt from contact records that share this company: name, job title, job level, job function and person location.
Turn cold outreach into meaningful business conversations.
Rated and recommended by professionals who expect more
Matching runs on fields we already have: industry, employee range, HQ location, ownership type, funding rounds, specialities. Results come live from the ReachStream directory.